Levetiracetam is an antiepileptic (SV2A ligand) indicated for partial-onset, myoclonic and primary generalized tonic-clonic seizures. We supply it to US manufacturers of tablets, extended-release tablets, oral solution and injection.
Data from PubChem (CID 5284583) and FDA’s substance registry
CAS number
102767-28-2
Molecular formula
C8H14N2O2
Molecular weight
170.2g/mol
FDA UNII
IUPAC name
(2S)-2-(2-oxopyrrolidin-1-yl)butanamide
InChIKey
HPHUVLMMVZITSG-LURJTMIESA-N
- Appearance
- White to off-white crystalline powder with a faint odor and a bitter taste.
- Solubility
- Very soluble in water (104 g per 100 mL). Freely soluble in chloroform and methanol, soluble in ethanol and sparingly soluble in acetonitrile.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
The single S-enantiomer; check the limit for the R-enantiomer. Doses run to grams a day, so it is bought in volume.
On the US market
- Reference product
- KeppraNDA 021035
- Approved ANDAs
- 66 with a marketed product
- Approved forms and strengths
- Tablet 250 mg, 500 mg, 750 mg, 1 g
- Injection 500 mg/100 mL, 500 mg/5 mL, 1 g/100 mL, 1.5 g/100 mL
- Extended-release tablet 500 mg, 750 mg
- Oral solution 100 mg/mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com
Sertraline Hydrochloride
Selective serotonin reuptake inhibitor (SSRI)
CAS 79559-97-0Escitalopram Oxalate
Selective serotonin reuptake inhibitor (SSRI)
CAS 219861-08-2Duloxetine Hydrochloride
Serotonin-norepinephrine reuptake inhibitor (SNRI)
CAS 136434-34-9Bupropion Hydrochloride
Norepinephrine-dopamine reuptake inhibitor
CAS 31677-93-7